Latest Breaking News On - Replimune group - Page 21 : comparemela.com

Form 10-K Replimune Group, Inc For: Mar 31

Form 10-K Replimune Group, Inc For: Mar 31
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesUnited kingdomRobert coffinJoseph slatteryJean franchiAndrew schwendenmanHyam levitskyPhilip astley sparkeChristopher sarchiSushil patelPaolo pucciKonstantinos xynosChristy oligerDieter weinandKapil dhingra

Form 8-K Replimune Group, Inc For: May 18

Form 8-K Replimune Group, Inc For: May 18
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAndrew schwendenmanPhilip astley sparkeJean franchiBusiness administrationSecurities exchangeBoard of directors the companyLife sciencesReplimune group incNasdaq stock marketCarbonite incCompany viceUniversity of massachusettsSonus networksWall streetSecurities exchange act

Form S-8 Replimune Group, Inc

Form S-8 Replimune Group, Inc
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCommonwealth of massachusettsJoseph slatterySander slootwegHyam levitskyDieter weinandChristopher sarchiJean franchiPhilip astley sparkeShawn gliddenBenjaminj steinKapil dhingraChristy oligerAndrew schwendenmanTimothyj corbettPaolo pucci

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

18.05.2023 - Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and Biologics License Application (BLA) submission on track .

United statesArleen goldenbergBristol myers squibbChris brinzeyJean franchiPhilip astley sparkeAndrew schwendenmanProgram highlights milestonesAmerican transplant congressExchange commissionSecurities exchangeCorporate communicationsReplimune group incVice presidentChief accountingSecurities act

Replimune Group, Inc (NASDAQ:REPL) Receives $51 67 Average Price Target from Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have received an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock […]

Piper sandlerNews ratings for replimune group dailyReplimune group incVanguard group incPricet rowe associates incEf hutton acquisition coReplimune groupT rowe price investment management incReplimune group company profileBlackrock incAnalyst recommendations for replimune groupReplimune group trading downGet ratingStreet corpPrice investment managementRowe price investment management